Fructosamine and HBA1c are recommended 932 Up To 932 H 932 .3 H 932 H 932 932 .7 932 L 932 932 .2 932 H 932 932 932 L 932 M .D Dr

932 1/2 Average : 932 .9 Average : 932 Average : 932 .1 932 Average : 932 Lipid Profile(T 932 932 .7 932 932 .5 932 932 .5 932 932 .5 932 L .5 932 L .5 932 Page 1 13 M .D Dr

932 932 - 932 932 "Non smoker up to 932 Smoker up to 932 N .B .: CEA Levels May Vary According To The Platform Used In The Analysis H 519 H 932 932 - 932 H 697 932 932 - 932 N .B .: "Screening Testing on Asymptomatic men : * PSA Screening may be carried out every two years Annual Testing for PSA levels above 932 .5 ng/ml H 398 932 453 932 M .D Dr

Positive 453 453 Negative : <0 Weak Positive : 932 .6 - 932 Positive : =>1 Negative 932 Negative : < 932 Weak positive : 0 .9 - <1 Positive : => 932 Positive >500 Negative : < 932 Weak positive : 0 .5 - 932 Positive : => 932 932 Negative : < 932 Weak Positive : 932 .9 - <1 Positive : => 932 M .D Dr

932 Negative: < 932 Weak Positive: 932.9 - <1 Positive: => 932 M.D Dr

932 932 .7 - 932 932 932 L 932 ml/min/1 932 H 932 Less than 932 N .B .:-Detectable level of Barbiturates: 300ng/ml -Detectable level of Cocaine: 300ng/ml -Detectable level of Amphetamine: 406 ng/ml -Detectable level of (THC): -Detectable level of Benzodiazepine: 300ng/ml -Detectable level of Opiates (Morphine): 453 ng/ml -The sample was provided to the lab -Positive result should be confirmed by another method (GC/MS) M .D Dr

M .D Dr

Comment: APCA is highly recommended N .B N .B N .B Dr

932 Negative <0 .8 Borderline 932 .8 - 932 Positive >1 N .B 932 N .B Dr

H 932 M .D Dr

N .B amplification and detection HBV DNA <20 IU/mL indicates that the HBV DNA level is below the limit of detection of the assay HBV DNA >170,000,000 IU/mL indicates that the HBV DNA level is above the limit of detection of the assay Note: The HBV DNA concentration in IU/mL X 932 .82 = HBV DNA in copies/mL N .B during treatment of patients with chronic hepatitis and patients undergoing antiviral therapy the (CAP/CTM) allowed for a better definition of viral kinetics for all HCV genotypes (1 - 6) Results are reported in international units (IU) 932 IU/ml Corresponds to approx .5 Copies/ml Viremia) test Fibro-Acti test and are recommended for Positive HCV patients N .B blood sample N .B (HCV) in human blood sample TMA for HCV RNA is recommended for negative HCV patients blood sample, which is more sensitive than other PCR qualitative assays a concentration of 932 .3 IU/mL would have been detected Fibro-Acti test and are recommended for Positive HCV patients Dr

N .B .:A single genetic defect rarely exerts a dramatic effect in the development of cardiovascular disease (CVD) detrimental polymorphism acting in synergy with unfavorable environmental factors by reverse hybridization of biotinylated amplification products to oligonucleotides probes on the test strip The assay covers the following mutation: FV G1691A (Leiden) N .B .:A single genetic defect rarely exerts a dramatic effect in the development of cardiovascular disease (CVD) detrimental polymorphism acting in synergy with unfavorable environmental factors by reverse hybridization of biotinylated amplification products to oligonucleotides probes on the test strip E2/E3/E4 Dr

Weak Positive 932 .0 - 932 Negative 932 UP to 932 Negative 932 UP to 932 Dr

932 < 932 * Negative for LA The test for LA is negative if the screen ratio is less than 932.2.N.B 453 932 932 932 932 93 932.9 - 932 932 Dr

Comment: Weak Positive, repetition of the test is recommended 932 or N .B 1- The analysis of a single test sample should not be used as the sole criteria for diagnosis based on the test result in conjunction with other clinical and or laboratory findings 2- In early infections detectable levels of antigen may be absent, the parasite load will determine the sensitivity of the test Dr